FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2431097705> ?p ?o ?g. }

• W2431097705 endingPage "1873" @default.
• W2431097705 startingPage "1865" @default.
• W2431097705 abstract "Purpose To assess the association of clinical and biological factors with extensive macular atrophy with pseudodrusen (EMAP) characterized by bilateral macular atrophy occurring in patients aged 50 to 60 years and a rapid progression to legal blindness within 5 to 10 years. Design A national matched case-control study. Participants Participants were recruited in 10 French Departments of Ophthalmology and their associated clinical investigation centers. All 115 patients with EMAP had symptoms before the age of 55 years due to bilateral extensive macular atrophy with a larger vertical axis and diffuse pseudodrusen. Three controls without age-related macular degeneration (AMD) or retinal disease at fundus examination were matched for each patient with EMAP by gender, age, and geographic area (in total 415). Methods Subjects and controls underwent an eye examination including color, red-free autofluorescent fundus photographs and spectral-domain optical coherence tomography with macular analysis. The interviews collected demographic, lifestyle, family and personal medical history, medications, and biological data. Associations of risk factors were estimated using conditional logistic regression. Main Outcome Measures Extensive macular atrophy with pseudodrusen status (cases vs. controls). Results Extensive macular atrophy with pseudodrusen most frequently affected women (70 women, 45 men). After multivariate adjustment, family history of glaucoma or AMD was strongly associated with EMAP (odds ratio [OR], 2.3, P = 0.008 and OR, 1.5, P = 0.01, respectively). No association was found with cardiac diseases or their risk factors. Mild and moderate kidney disease and higher neutrophil rate were associated with a reduced risk of EMAP (OR, 0.58, P = 0.04; OR, 0.34, P = 0.01; and OR, 0.59, P = 0.003, respectively). On the contrary, eosinophilia (OR, 1.6; P = 0.0002), lymphocytosis (OR, 1.84; P = 0.0002), increased erythrocyte sedimentation rate (OR, 6.5; P = 0.0005), decreased CH50 (P = 0.001), and high plasma C3 level (P = 0.023) were significantly associated with a higher risk of EMAP. Conclusions This study documents an association between EMAP and family history of AMD and glaucoma, a clear female predominance, and a systemic inflammatory profile. The reduced CH50 and increased C3 plasma values could reflect a more severe complement pathway dysfunction than in AMD, leading to early pseudodrusen and rapid development of geographic atrophy. There is no association of EMAP with AMD cardiac diseases or cardiac risks, including cigarette smoking. To assess the association of clinical and biological factors with extensive macular atrophy with pseudodrusen (EMAP) characterized by bilateral macular atrophy occurring in patients aged 50 to 60 years and a rapid progression to legal blindness within 5 to 10 years. A national matched case-control study. Participants were recruited in 10 French Departments of Ophthalmology and their associated clinical investigation centers. All 115 patients with EMAP had symptoms before the age of 55 years due to bilateral extensive macular atrophy with a larger vertical axis and diffuse pseudodrusen. Three controls without age-related macular degeneration (AMD) or retinal disease at fundus examination were matched for each patient with EMAP by gender, age, and geographic area (in total 415). Subjects and controls underwent an eye examination including color, red-free autofluorescent fundus photographs and spectral-domain optical coherence tomography with macular analysis. The interviews collected demographic, lifestyle, family and personal medical history, medications, and biological data. Associations of risk factors were estimated using conditional logistic regression. Extensive macular atrophy with pseudodrusen status (cases vs. controls). Extensive macular atrophy with pseudodrusen most frequently affected women (70 women, 45 men). After multivariate adjustment, family history of glaucoma or AMD was strongly associated with EMAP (odds ratio [OR], 2.3, P = 0.008 and OR, 1.5, P = 0.01, respectively). No association was found with cardiac diseases or their risk factors. Mild and moderate kidney disease and higher neutrophil rate were associated with a reduced risk of EMAP (OR, 0.58, P = 0.04; OR, 0.34, P = 0.01; and OR, 0.59, P = 0.003, respectively). On the contrary, eosinophilia (OR, 1.6; P = 0.0002), lymphocytosis (OR, 1.84; P = 0.0002), increased erythrocyte sedimentation rate (OR, 6.5; P = 0.0005), decreased CH50 (P = 0.001), and high plasma C3 level (P = 0.023) were significantly associated with a higher risk of EMAP. This study documents an association between EMAP and family history of AMD and glaucoma, a clear female predominance, and a systemic inflammatory profile. The reduced CH50 and increased C3 plasma values could reflect a more severe complement pathway dysfunction than in AMD, leading to early pseudodrusen and rapid development of geographic atrophy. There is no association of EMAP with AMD cardiac diseases or cardiac risks, including cigarette smoking." @default.
• W2431097705 created "2016-06-24" @default.
• W2431097705 creator A5005381560 @default.
• W2431097705 creator A5007724266 @default.
• W2431097705 creator A5009733412 @default.
• W2431097705 creator A5012930249 @default.
• W2431097705 creator A5013729728 @default.
• W2431097705 creator A5015786602 @default.
• W2431097705 creator A5017578766 @default.
• W2431097705 creator A5021186827 @default.
• W2431097705 creator A5021294516 @default.
• W2431097705 creator A5021422523 @default.
• W2431097705 creator A5021430835 @default.
• W2431097705 creator A5021952183 @default.
• W2431097705 creator A5025442808 @default.
• W2431097705 creator A5030933219 @default.
• W2431097705 creator A5031339229 @default.
• W2431097705 creator A5032351808 @default.
• W2431097705 creator A5034082446 @default.
• W2431097705 creator A5035602376 @default.
• W2431097705 creator A5042826579 @default.
• W2431097705 creator A5042899138 @default.
• W2431097705 creator A5046347482 @default.
• W2431097705 creator A5053183041 @default.
• W2431097705 creator A5055829463 @default.
• W2431097705 creator A5060142133 @default.
• W2431097705 creator A5061783443 @default.
• W2431097705 creator A5061836464 @default.
• W2431097705 creator A5062977262 @default.
• W2431097705 creator A5072519615 @default.
• W2431097705 creator A5079061984 @default.
• W2431097705 creator A5080253786 @default.
• W2431097705 creator A5083982156 @default.
• W2431097705 creator A5084105951 @default.
• W2431097705 creator A5085464248 @default.
• W2431097705 creator A5086662698 @default.
• W2431097705 date "2016-09-01" @default.
• W2431097705 modified "2023-10-08" @default.
• W2431097705 title "Clinical Characteristics and Risk Factors of Extensive Macular Atrophy with Pseudodrusen" @default.
• W2431097705 cites W1426387254 @default.
• W2431097705 cites W1580331077 @default.
• W2431097705 cites W168181582 @default.
• W2431097705 cites W183193446 @default.
• W2431097705 cites W1877983131 @default.
• W2431097705 cites W1934543195 @default.
• W2431097705 cites W1965478508 @default.
• W2431097705 cites W1967034717 @default.
• W2431097705 cites W1980751081 @default.
• W2431097705 cites W1987772140 @default.
• W2431097705 cites W1988962811 @default.
• W2431097705 cites W1994333720 @default.
• W2431097705 cites W1996228206 @default.
• W2431097705 cites W2001661375 @default.
• W2431097705 cites W2011845506 @default.
• W2431097705 cites W2020256864 @default.
• W2431097705 cites W2020344616 @default.
• W2431097705 cites W2028982261 @default.
• W2431097705 cites W2032463068 @default.
• W2431097705 cites W2036870834 @default.
• W2431097705 cites W2038256884 @default.
• W2431097705 cites W2039628200 @default.
• W2431097705 cites W2049823525 @default.
• W2431097705 cites W2055864845 @default.
• W2431097705 cites W2061510118 @default.
• W2431097705 cites W2065895674 @default.
• W2431097705 cites W2069424414 @default.
• W2431097705 cites W2076103048 @default.
• W2431097705 cites W2084450231 @default.
• W2431097705 cites W2091832434 @default.
• W2431097705 cites W2093802575 @default.
• W2431097705 cites W2096141126 @default.
• W2431097705 cites W2107578685 @default.
• W2431097705 cites W2111379072 @default.
• W2431097705 cites W2117957338 @default.
• W2431097705 cites W2119823595 @default.
• W2431097705 cites W2124361658 @default.
• W2431097705 cites W2129702134 @default.
• W2431097705 cites W2133904455 @default.
• W2431097705 cites W2147322584 @default.
• W2431097705 cites W2158743328 @default.
• W2431097705 cites W2167599764 @default.
• W2431097705 cites W2191055194 @default.
• W2431097705 cites W2266184360 @default.
• W2431097705 cites W2318536379 @default.
• W2431097705 cites W96660166 @default.
• W2431097705 doi "https://doi.org/10.1016/j.ophtha.2016.05.018" @default.
• W2431097705 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27320518" @default.
• W2431097705 hasPublicationYear "2016" @default.
• W2431097705 type Work @default.
• W2431097705 sameAs 2431097705 @default.
• W2431097705 citedByCount "10" @default.
• W2431097705 countsByYear W24310977052018 @default.
• W2431097705 countsByYear W24310977052021 @default.
• W2431097705 countsByYear W24310977052022 @default.
• W2431097705 countsByYear W24310977052023 @default.
• W2431097705 crossrefType "journal-article" @default.
• W2431097705 hasAuthorship W2431097705A5005381560 @default.
• W2431097705 hasAuthorship W2431097705A5007724266 @default.

• next